Pharmagreen Biotech Inc
Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company's primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue … Read more
Pharmagreen Biotech Inc (PHBI) - Total Liabilities
Latest total liabilities as of June 2025: $2.67 Million USD
Based on the latest financial reports, Pharmagreen Biotech Inc (PHBI) has total liabilities worth $2.67 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmagreen Biotech Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how Pharmagreen Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmagreen Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Pharmagreen Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gaon Group Ltd
TA:GAGR
|
Israel | ILA604.16 Million |
|
SBC Medical Group Holdings Incorporated
NASDAQ:SBCWW
|
USA | $73.30 Million |
|
Fimperkasa Utama Tbk PT
JK:FIMP
|
Indonesia | Rp5.07 Billion |
|
CHESAPEAKE UTIL
BE:CH5
|
Germany | €2.09 Billion |
|
STATE STREET - Dusseldorf Stock Exchang
DU:ZYA
|
Germany | €312.65 Billion |
|
OSHKOSH
BE:OK3
|
Germany | €5.77 Billion |
|
SRIVARU Holding Limited
PINK:SVUHF
|
USA | $1.54 Million |
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
Korea | ₩25.13 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Pharmagreen Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 27.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmagreen Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmagreen Biotech Inc (2008–2024)
The table below shows the annual total liabilities of Pharmagreen Biotech Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $3.23 Million | +40.34% |
| 2023-09-30 | $2.30 Million | +13.35% |
| 2022-09-30 | $2.03 Million | -1.65% |
| 2021-09-30 | $2.07 Million | -35.45% |
| 2020-09-30 | $3.20 Million | +118.49% |
| 2019-09-30 | $1.46 Million | -20.26% |
| 2018-09-30 | $1.84 Million | +1913.62% |
| 2017-09-30 | $91.22K | +703.66% |
| 2009-09-30 | $11.35K | +1048.89% |
| 2008-09-30 | $988.00 | -- |